Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2026)

Amneal Pharmaceuticals has reported Receivables for 10 years, with the latest figure at $1.6 billion in Q2 2026.

• On a quarterly basis, Receivables rose 19.19% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 19.19% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 34.88% from the prior year.
• Receivables was $1.6 billion for Q2 2026 at Amneal Pharmaceuticals, up from $1.5 billion in the prior quarter.
• The five-year high for Receivables was $1.8 billion in Q4 2025, with the low at $613.7 million in Q4 2023.
• Average Receivables over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables tumbled 54.37% in 2023, then jumped 126.16% in 2025.
• Over 5 years, Receivables stood at $1.3 billion in 2022, then slumped by 54.37% to $613.7 million in 2023, then gained by 27.12% to $780.2 million in 2024, then surged by 126.16% to $1.8 billion in 2025, then dropped by 8.48% to $1.6 billion in 2026.
• The last three Receivables figures came in at $1.6 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.